Oncology preclinical models
Cancer in vitro assays:
In vitro efficacy testing:
– Growth inhibition
– Cytotoxicity activity
Cytometry analysis / Non-adherent cells:
– ALDH activity
– Specific stainings
Transplantation mouse models:
In-house in vitro facility
Cells preparation / Cell line amplification
– Cells counting and control prior injection
– Primary tumour following SC / orthotopic implantation
Metastasis dissemination following ortho. / IV / IP / IC injections
Syngeneic models / examples
Breast adenocarcinoma: 4T1 / Balb/c mice
Pancreas carcinoma: TGP49
Melanoma: B16 & B16F10 / C57BL/6
Xenograft models / examples
Acute Myeloid Leukemia / AML: MOLM-14 cell line
Pancreas carcinoma: Mia-Pa-Ca / Panc-1 cell lines
Breast adenocarcinoma: MDA-MB-231 cell line
Melanoma: A375 cell line
Lung carcinoma: A549 cell line
Tumour / Metastasis dissemination / in vivo evaluation
Tumour volume / Caliper measurement
Bioluminescence BLI / Fluorescence FLI
Fluorescence Tomography (FMT)
Ultrasound high & low resolution
PECT/CT (99mTc, 111In, 123I, 201Th / Dual detection possible)
PET/CT (18F / FDG)
Micro-angiography (terminal)
Tumour characterization / ex vivo:
Cytometry (AML)
Histology / IHC / Histomorphometry
– Tumour morphology HES
– Vascularization / Angiogenesis / IHC CD31/CD34
– Leucocyte infiltration / IHC CD45
– Proliferation index / IHC Ki-67
For additional informations on these models or on other preclinical models in the oncology area, please inquire.